跳至主要内容
临床试验/NCT00099723
NCT00099723终止1 期

The Effect of a Probiotic on Hepatic Steatosis

VSL Pharmaceuticals2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2004年10月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
终止
发起方
入组人数
30
试验地点
2
主要终点
MRI

研究概览

简要总结

Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States. The exact cause of NAFLD is unknown, but it is more common among people with conditions such as adult-onset diabetes. NAFLD can strike people of all ages but most often affects adults between the ages of 40 and 60. Research indicates that overgrowth of gut bacteria can start a chain of biological processes that stress the liver, causing liver inflammation. Probiotics, living bacteria taken orally, may decrease the stress on the liver by reducing this bacterial overgrowth and/or strengthening the gut walls. Because probiotics are generally safe, inexpensive, and easy to tolerate they are an attractive treatment option for NAFLD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double

入排标准

年龄范围
45 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult-onset diabetes
  • Liver biopsy in the previous 2 months with diagnosis of fatty liver and fibrosis stage F2-F3

排除标准

  • There are multiple exclusion criteria.

结局指标

主要结局

MRI

Liver biopsy

Blood work

次要结局

未报告次要终点

研究者

发起方
VSL Pharmaceuticals
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验